Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.34    
    

        Immunicon Corp. (CRO)  

 AND  

 Igeneon Krebs-Immuntherapie Forschungs—

und Entwicklungs-AG (Sponsor)  

 Master Services Agreement  

THIS AGREEMENT is made 

BETWEEN:  

        (1)   Immunicon
Corp. the registered office which is situated at 3401 Masons Mill Road Huntingdon Valley, PA 19006 ("CRO"); and 

        (2)   IGENEON
Krebs-Immuntherapie Forschungs- und Entwicklungs AG, Brunner Str.59, A-1230 Vienna ("Sponsor"). 

WHEREAS:  

        (A)  The
Sponsor is responsible for the initiation, management, and/or financing of Clinical Trials. 

        (B)  CRO
has established a method of determining disseminated tumor cells in peripheral blood and bone marrow that has proven not to interfere with the immune response
generated by the Sponsor's IGN101 vaccine. 

        (C)  The
Sponsor may request CRO from time to time to undertake Services related to the provision of clinical trials. 

        (D)  Where
CRO agrees to undertake the Services it will be on the terms and conditions set out in this Agreement. 

WHEREBY IT IS AGREED as follows: 

1.     Definitions  

        The following expressions, which are frequently used in this Agreement, shall have the meanings attributed to them below. Other less frequently used expressions
are defined in the body of this Agreement. 

	Expression
 
	 	Meaning
 

	"Assay"	 	means the System of laboratory analysis of CRO to determine and quantity disseminated tumor cells in Samples of peripheral blood or bone marrow.
	

"Clinical Trial"	
 	

means the clinical trial as detailed in a Protocol.
	

"Change Order"	
 	

means a minor amendment or addition to any Order. This can be requested by either party and must be agreed in writing through a Change Order Form before implementation.
	

"Ethics Committee"	
 	

has the same meaning as it does in the ICH Guideline
	

"Essential Document"	
 	

has the same meaning as it does in the ICH Guideline.
	

"Effective Date"	
 	

is XXXX.
	

"Good Clinical Practice"	
 	

has the same meaning ascribed to it in the ICH Guideline.
	

"Good Laboratory Practice"	
 	

has the same meaning ascribed to it in the Guidance for Industry and the Good Laboratory Practice ICH Guidelines.
	 	 	 	 	 

	

"ICH Guideline"	
 	

means the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) as the same may be amended or re-issued from time to time.
	

"Investigators"	
 	

means those registered medical practitioners responsible for the conduct of Clinical Trials at Trial Sites. In the event that a Clinical Trial is conducted by a team of individuals at a Trial Site, all of the team members are Investigators and the
Investigator leading the team, when referred to separately from the other Investigators, will be called the Principal Investigator.
	

"Investigational Product"	
 	

has the same meaning as it does in the ICH Guideline.
	

"Materials"	
 	

means any and all materials provided by the Sponsor to the Investigators in connection with this Agreement including but not limited to any Investigational Product.
	

"Modification"	
 	

means a major change to any Order or Service that requires a new Order to be agreed.
	

"Order"	
 	

means a request made by the Sponsor to CRO for CRO to arrange for the Services to be provided in respect of a Clinical Trial which is accepted by CRO on the terms detailed in a Clinical Trial Order in the form detailed in the Schedules
One.
	

"Proprietary Information"	
 	

means:—
	

 	
 	

(a)	
 	

in the case of CRO, any and all information which is now or at any time hereafter in the possession of CRO and which relates to the Assay and System and CRO's business, including without limitation research, data, know-how, formulae, technical
operations, processes, designs, patents, photographs, drawings, specifications, software programmes, samples, other matters related to CRO's business and any other material bearing or incorporating any information relating to the System;
	 	 	 	 	 

	

 	
 	

(b)	
 	

in the case of the Sponsor, any and all information which is now or at any time hereafter in the possession of the Sponsor and which relates to the Sponsor's business including without limitation, research, data, know-how, formulae, technical
operations, processes, designs, patents, photographs, drawings, specifications, software programmes, samples, other matters related to the Sponsor's business and any other material bearing or incorporating any information relating to the Sponsor's
Business.
	

"Protocol"	
 	

means a document appended to an Order which may (subject to the approval of the Ethics Committee or appropriate regulatory authority) be amended from time to time providing the background, rationale, and objective(s) of a Clinical Trial and describes
its design, methodology, and organisation, including statistical considerations. Following any such amendment references to "the Protocol" shall be deemed to mean the Protocol so amended.
	

"Services"	
 	

means the services to be performed by CRO or the Investigators as set out in the relevant Order as may be amended from time to time by written agreement between the Sponsor and CRO.
	

"Samples"	
 	

means the samples of Trial Subjects that are subject to the determination of disseminated tumor cells according to the CRO's SOP, which samples are either samples of peripheral blood or bone marrow.
	

"SOP"	
 	

means standard operating procedure for determining disseminated tumor cells in peripheral bood or bone marrow, including logistics, sample management, assay performance, formate of the results and archiving of data.
	 	 	 	 	 

	

"System"	
 	

means the data bases, know-how, systems and procedures and specialised staffing structure developed by CRO for use in connection with the support of clinical trials including the logistics to quantity disseminated tumor cells in samples within a
predefined time, and the SOP for providing the Services.
	

"Trial Subject"	
 	

means an individual who participates in a Trial either as a recipient of an Investigational Product or as a control.
	

"Trial Site"	
 	

means the location(s) where Clinical Trial Activities are actually conducted.

        In
this Agreement the singular includes the plural and vice versa. 

        The
clause headings are for ease of reference only and do not form part of this Agreement for the purposes of its interpretation or construction. 

2.     Terms and Scope of Agreement  

        2.1   This
Agreement shall commence on the Effective Date and shall continue until terminated in accordance with clause 13 below. 

        2.2   All
Orders placed by the Sponsor and accepted by CRO shall be subject to the terms and conditions of this Agreement as varied or added to by the terms of the relevant
Order. 

        2.3   Save
where expressly varied by the terms of this Agreement or the Order or the Protocol, the obligations of the Sponsor and Investigators in connection with Clinical
Trials shall include those detailed in the ICH Guideline. 

3.     System  

        3.1   CRO
shall ensure that: 

        (a)   the
Assay is appropriately qualified and validated as required by Good Laboratory Practice; 

        (c)   it
is capable of, and have the time, commitment, skills, experience, approval or consents necessary to carry out the Services; 

        (d)   it
has all appropriate facilities and staff necessary to carry out the Services including the management of Samples for laboratory analysis; 

        (f)    will
comply with the monitoring and review procedures (including source data verification) detailed in clause 7 of this Agreement; 

4.     Services  

        4.1   From
time to time the Sponsor may place an Order with CRO. 

        4.2   CRO
shall use its reasonable endeavours to ensure that the work is carried out: 

        (a)   in
accordance with the requirements specified in the Protocol and the Order, and subject to clause 5.2, and any other reasonable instructions of the Sponsor
including without limitation the Sponsor's standard operating procedures; 

        (b)   in
accordance with:— 

          (i)  Good
Laboratory Practice and Good Clinical Practice; 

         (ii)  the
ICH Guidelines; 

        (iii)  all
relevant laws, regulations and directions in operation in each country in which the Services are being provided; 

        c)     to
the time lines set out in the Order. 

        4.3   CRO
shall use its reasonable endeavours to ensure that it will: 

        (b)   promptly
disclose to the Sponsor any unexpected or unusual results or observations arising from Services in accordance with the procedure and requirements specified in
the Protocol and the Order; 

        (c)   report
as soon as reasonably practicable to the Sponsor the occurrence of any event either within or beyond their control which is likely to affect the carrying out of
Services in accordance with this Agreement and the Order; 

        (d)   liaise
with the Sponsor as directed in the Protocol or in the Order and as reasonably required by the Sponsor from time to time. 

5.     Changes to Services and Trial Sites  

        5.1   Either
party may request a minor amendment or addition to the Services and the related SOP at any time by written notice. This request shall be referred to as a Change
Order. 

        5.2   After
consultation, each party will agree in writing to the proposed amendment or addition, indicating any alterations to the Order considered necessary as a consequence
of the proposed change. The details of such alterations, such as, but not limited to, the cost or nature of the Services, shall be agreed in a Change Order Form, to be signed by both parties. 

        5.3   CRO
shall not implement amendments or additions to the Services and the related SOP until changes and any consequential changes to the terms of the Order have been
agreed and confirmed in a Change Order Form by CRO and the Sponsor. 

        5.4   If
the magnitudes of the amendments or additions to the Services are such that they represent a major change to the basic terms of the Order—such as but not
limited to the issuing of a new protocol or a prolonged delay in the commencement of the Order—CRO reserves the right to define this as a Modification of the terms of the Order. Under
these conditions, both parties will agree that a new Order will be prepared to take account of the changed conditions and terms of the Services. 

6.     Essential Documents and Materials  

        6.1   The
Sponsor will supply to CRO all those Essential Documents and Materials that are necessary to enable CRO to carry out the Services in accordance with this Agreement,
the Order and the Protocol. 

        6.2   The
Sponsor and CRO will comply with their obligations under the Protocol and the Order. 

7.     Monitoring Audit and Regulatory Authority Inspection  

        7.1   The
Sponsor and CRO agree that the Sponsor (and any duly appointed contractors of the Sponsor of whom CRO have received prior written notice) shall monitor and be
entitled to audit the conduct of the Services within normal working hours by the CRO and upon reasonable prior written notice to the CRO. Such monitoring and auditing may take such form as the Sponsor
reasonably thinks fit and shall include without limitation the right to inspect any facility used for the Services and to examine any procedures and records relating to the Services. 

        7.2   Unless
otherwise agreed by CRO the Sponsor in any event shall give not less than 3 business days prior written notice to CRO of its intention to monitor and/or audit. 

        7.3   In
the event that any regulatory authority having jurisdiction over or an interest in the conduct of the Clinical Trials carries out or gives notice of its intention to
carry out any inspection or investigation of CRO, or otherwise takes any action in relation to a Clinical Trial, CRO shall as soon as reasonably practicable notify the Sponsor in detail of the action
being taken or proposed. The Sponsor and CRO shall co-operate with any such inspection or investigation. The Sponsor shall have the right to be present at any such inspection or
investigation and to participate in any action arising therefrom. 

8.     Data/Confidentiality  

        8.1   All
data and work product relating to the Services performed hereunder, including all case report forms, data, documentation, information, materials and results in
whatever form generated during the conduct of all Studies under an Order hereunder, shall be owned by the party generating them. The Sponsor owns all clinical data from patients' case report forms,
data, documentation, information, materials and results in whatever form that relates to the Investigational Product and its clinical use. CRO is hereby granted a irrevocable, royalty-free
world-wide right and unrestricted license to utilize all such case report forms, data, documentation, information, materials and results in whatever form that relates to the
Investigational Product and its clinical use for all research and regulatory purposes, as may be necessary to file and obtain regulatory approvals of its Assay and System and any product or service
related thereto. CRO owns all data, documentation, information, materials and results in whatever form which relates to the processing of Samples to carry out the Services. The Sponsor is hereby
granted an irrevocable, royalty-free, world-wide right and unrestricted license to utilize all such data, documentation, information, materials and results in whatever form
that relates to the processing of Samples to carry out the Services for all research and regulatory purposes, as may be necessary to file and obtain regulatory approvals of its Investigational
Product. In consideration of CRO disclosing information relating to the Assay and System to the Sponsor and in consideration of the Sponsor disclosing information relating to the Sponsor's business to
CRO, both CRO and the Sponsor will accordingly not directly or indirectly use or disclose any of the Proprietary Information in whole or in part save for the purposes of and in accordance with this
Agreement. The submission of information to regulatory authorities for the purpose of filing for a regulatory approval of the System and/or any components thereof and the Investigational Product shall
not be considered as a disclosure subject to this clause 8.1. 

        8.2   The
foregoing restrictions on the recipient shall not apply to any Proprietary Information which: 

the
recipient can prove by documentary evidence produced to CRO or the Sponsor as the case may be that such Proprietary Information was already in the possession of the recipient and at its free
disposal before the disclosure hereunder to the recipient; 

        (b)   is
hereafter disclosed to the recipient without any obligations of confidence by a third party who has not derived it directly or indirectly from CRO or the Sponsor as
the case may be; 

        (c)   is
or becomes generally available to the public through no act or default on the part of the recipient or the recipient's contractors or employees; 

        (d)   is
required to be disclosed by any Court or Tribunal or under any statutory regulatory or similar legislative requirements subject to the imposition of obligations of
confidentiality wherever reasonably practicable provided that in the event of disclosure under this clause 8.2(d) the recipient promptly notifies CRO or the Sponsor as the case may be of any
request for such disclosure and details of exactly what disclosure is made; 

        (e)   which
the recipient reasonably requires to disclose in order to use the results of the Clinical Trial for regulatory purposes. 

        8.3.  On
request of CRO or the Sponsor, as the case may be, made at any time shall deliver to CRO or the Sponsor as the case may be all documents and other material in the
possession, custody or control of the recipient that bear or Incorporate any part of the Proprietary Information except for those materials reasonably required by the Sponsor to enable the use of the
results of the Clinical Trial 

for
regulatory or promotional purposes; provided, however, that one (1) copy of all such documents and other material may be retained in the files of legal counsel for CRO or the Sponsor as the
case may be in order to verify each party's obligations with respect to Proprietary Information under this Article 8. 

9.     Publications  

        9.1   Any
formal presentation or publication of data collected as a direct or indirect result of the Services under this Agreement will be considered as a joint publication by
the Investigator(s) and the appropriate personnel of Sponsor and CRO. Authorship will be determined by mutual agreement. Any intended communication shall be received by both Sponsor and CRO reasonably
in advance of submission for publication (at least 15 working days for an abstract or material to be presented orally and 45 working days for a manuscript). This request is made so as to allow review
of the communications for accuracy (thus avoiding potential discrepancies with submissions to regulatory authorities), to verify that Proprietaryl Information is not inadvertently being divulged, to
allow adequate input or supplementary information that may not have been available to the Investigator(s), and to allow establishment of co-authorship. A manuscript for publication has to
be jointly finalized within 1 year after termination of the Clinical Trial performed to which the publication relates. 

        9.2   Neither
Sponsor nor CRO shall use the name or trademark of the other party in any publicity, advertising or news release without the prior written approval of that other
party. 

10.   Intellectual Property Rights  

        10.1 All
inventions, discoveries, improvements and original works conceived or made by CRO in the course of providing the Services shall be owned by the CRO; provided,
however that for any of the foregoing that relate directly to the Investigational Product, CRO hereby grants Sponsor an exclusive, royalty-free, unrestricted world-wide
license, with the right to sublicense, to utilize any such inventions, discoveries, improvements and original works that relate directly to the Investigational Product to develop, make, have made,
use, sell, import and export the Investigational Product. 

        10.2 CRO
acknowledges that it has no right in any Investigational Product or the Essential Documents supplied by the Sponsor to the Investigators all of which shall be
regarded by CRO as the property of the Sponsor and CRO shall, at the request and expense of the Sponsor, execute all such documents and deeds and do all such things as may be necessary or desirable to
give full effect to the foregoing. 

        10.3 The
Sponsor acknowledges that it has no right to the Assay or the System or any part thereof all of which shall be regarded by the Sponsor as the exclusive property of
CRO and the Sponsor shall, at the request and expense of CRO, execute all such documents and deeds and do all such things as may be necessary or desirable to give full effect to the foregoing.
Provided, however, CRO shall grant Sponsor the right to use free of charge any information reasonably required to use the results of the Clinical Trial for regulatory or promotional purposes, subject
to the restrictions regarding the use of Proprietary Information set forth in this Agreement. 

11.   Indemnity and Compensation for Injury  

        11.1 By
Sponsor 

        11.1.1 In
consideration of the participation by CRO and any approved contractors in providing the Services and subject to clause 11.2 below, the Sponsor will fully
indemnify and hold harmless CRO against all claims and proceedings (to include any settlements or ex gratia payments made with the consent of the Sponsor and all legal and expert costs and expenses)
made or brought (whether successful or otherwise) by or on behalf of Trial Subjects taking part in Clinical Trials (or their dependants Estate or Personal Representatives) against CRO and its staff
and contractors for personal injury (including death) to Trials Subjects arising out of or relating to the Clinical Trials, the administration of the Investigational Product(s) or any clinical
intervention or procedure provided for 

or
required by the Protocol to which the Trial Subjects would not have been exposed but for their participation in the Clinical Trial. 

        11.1.2 The
above indemnity by the Sponsor shall not apply to any such claim or proceedings: 

        (a)   to
the extent that such personal injury (including death) is caused by the grossly negligent or willfull acts or omissions or breach of statutory duty of CRO and its
staff and contractors; 

        (b)   to
the extent that such personal injury (including death) is caused by the failure of CRO and its staff and contractors to conduct the Clinical Trial in accordance with
the Protocol; 

        (c)   unless
as soon as reasonably practicable following receipt of notice of such claim or proceeding, CRO and its staff and contractors notify the Sponsor in writing of it
and upon the Sponsor's request, and at the Sponsor's sole cost, give the Sponsor the option to have full care and control of the claim or proceedings using legal representation of its own choosing,
such option to be exercised by giving written notice to CRO within ten days from receipt of notice of such claim or proceeding from CRO; 

        (d)   if
CRO and its staff and contractors shall have made any admission in respect of such claim or proceedings or taken any action relating to such claim or proceeding
prejudicial to the defence of it
without the written consent of the Sponsor, such consent shall not be unreasonably withheld. Provided that this condition shall not be treated as breached by any statement properly made by CRO and its
staff and contractors in connection with the operation of complaints procedures, accident reporting procedures or disciplinary procedures or where such statement is required by law or regulations of a
governmental authority. 

        11.1.3 The
Sponsor or CRO, as the case may be, shall keep CRO or the Sponsor, as the case may be, and its staff and contractors and their respective legal advisers fully
informed of the progress of any such claim or proceedings, will consult fully with the other party and its staff and contractors on the nature of any defence to be advanced. 

        11.1.4 Without
prejudice to the provisions of clause 11.2 above, CRO will use its reasonable endeavours to inform the Sponsor promptly of any circumstances reasonably
thought likely to give rise to any such claim or proceedings of which it is directly aware and shall keep the Sponsor reasonably informed of developments in relation to any such claim or proceedings
even where CRO decides not to make a claim under this indemnity. Likewise, the Sponsor shall use its reasonable endeavours to inform CRO of any such circumstances and shall keep CRO reasonably
informed of developments in relation to any such claim or proceeding made or brought against the Sponsor alone. 

        11.1.5 CRO
and the Sponsor will each give to the other such help as may reasonably be required for the efficient conduct and prompt handling of any claim or proceedings by
or on behalf of the Trial Subjects (or their dependants Estate or Personal Representatives) or concerning such a declaration as is referred to in clause 11.2(b) above. 

        11.2 By
CRO 

        11.2.1 CRO
will fully indemnify and hold harmless the Sponsor and its affiliates, agents, officers and employees from and against all claims and proceedings (to include any
settlements or ex gratia payments made with the consent of CRO and all legal and expert costs and expenses) made or brought (whether successful or otherwise) by or on behalf of Trial Subjects taking
part in Clinical Trials (or their dependants Estate or Personal Representatives) against the Sponsor, its staff or contractors for personal injury (including death) to Trials Subjects arising out of
or relating to the Clinical Trials, the administration of the Investigational Product(s) or any clinical intervention or procedure provided for or required by the Protocol to which the Trial Subjects
would not have been exposed but for their participation in the Clinical Trial, which result directly from the gross negligence or wilful default of CRO in the performance of this Agreement. 

        11.2.2 The
above indemnity by CRO shall not apply to any such claim or proceedings:- 

        (a)   to
the extent that such personal injury (including death) is caused by the negligent or willful acts or omissions or breach of statutory duty of the Sponsor and its
staff and contractors or to the extent that such personal injury (including death) is caused by procedures conducted in accordance with the Protocol; 

        (b)   unless
as soon as reasonably practicable following receipt of notice of such claim or proceeding, the Sponsor and its staff and contractors notify CRO in writing of it
and upon CRO's request, and at CRO's sole cost, give CRO the option to have full care and control of the claim or proceedings using legal representation of its own choosing, such option to be
exercised by giving written notice to the Sponsor within ten days from receipt of notice of such claim or proceeding from the Sponsor: 

        (d)   if
the Sponsor and its staff and contractors shall have made any admission in respect of such claim or proceedings or taken any action relating to such claim or
proceeding prejudicial to the defence of it without the written consent of CRO, such consent shall not be unreasonably withheld. Provided that this condition shall not be treated as breached by any
statement properly made by the Sponsor and its staff and contractors in connection with the operation of complaints procedures, accident reporting procedures or disciplinary procedures or where such
statement is required by law or regulations of a governmental authority. 

12.   Payment  

        12.1. CRO
will perform the Services at its own cost and expense, including transfer of Samples from the trial sites to its facility, and archiving of data. 

13.   Termination Provisions  

        13.1 Either
party shall be entitled to terminate this Agreement forthwith by written notice to the other in accordance with clause 15 below:— 

        (a)   if
the other party commits an irremediable breach of this Agreement or commits a remediable breach of this Agreement but fails to remedy the breach within 30 days
of receiving written notice from the other requiring such remedy; 

        (b)   if
the other party shall become insolvent by reason of its inability to pay its debts as they fall due or shall go into liquidation whether voluntary or compulsorily
other than for the purposes of a solvent reconstruction or amalgamation or shall make any arrangement or compulsion with its creditors or shall have an Administrator and/or Administrative Receiver
appointed of all or any part of its assets or takes or suffers any similar action in consequence of a debt or suffers distress or execution to be levied or threatened on any of its property; 

        (c)   if
either party ceases or takes steps to cease carrying on its business; 

        (d)   if
entitled to pursuant to clause 17.2 of this Agreement. 

        13.2 if
the Sponsor terminates any Order, or any part of an Order, or this Agreement other than for reasons described in clause 13.1, the Sponsor shall pay to CRO a
sum equivalent to: 

        (b)   full
payment for Services carried out to date at the point of termination and any work which cannot be immediately cancelled. 

        (c)   all
reasonable costs incurred in terminating the Order and carrying out the requirements set out in Clause 12.3. Both parties will agree these sums in a Change
Order form signed within 30 (thirty) working days of the date of termination. 

        13.3 Upon
termination of this Agreement or cancellation of any Order for whatever reason CRO shall use its reasonable endeavours to ensure— 

        (a)   the
return to the Sponsor of any remaining Materials in accordance with the Sponsor's instructions; 

        (c)   that
the Investigators make available for collection or return or forward to the Sponsor any and all documentation used to record data collected during the carrying out
of the Services, papers and/or reports in documentary or written form including any and all extracts, photocopies and abstracts of the same within sixty (60) days of termination or cancellation
or such period as is agreed. CRO may retain copies of such data and documents to the extent that such retention is reasonably necessary for regulatory or insurance purposes subject to compliance with
clause 7. 

        13.4 Provided
that where an Order is cancelled but this Agreement remains in force the provisions of Clauses 12.3 and 13.2 (c) shall only apply in so far as they
relate to the cancelled Order. 

        Upon
termination of this Agreement or cancellation of any Order for breach or insolvency on the part of CRO, CRO shall assist the Sponsor in entering into arrangements with other CROs to
permit the completion of the Clinical Trial. Termination of this Agreement shall not affect any rights or obligations of CRO, the investigators or the Sponsor that may have accrued prior to
termination. Clause 7, 8, 9, 10 and 11 of this Agreement shall survive the termination or expiry of this Agreement. 

14.   Assignment and Sub-contracts  

        14.1 CRO
shall not assign or sub-contract any of its rights, duties or obligations whatsoever or any part or parts herein contained without the prior written
consent of the Sponsor, which consent shall not be unreasonably withheld. 

        14.2 If
the Sponsor gives consent to sub-contract, CRO shall remain responsible for performance by its sub-contractor. CRO shall obtain from its
sub-contractor a signed undertaking to the Sponsor to observe the confidentiality restrictions in this Agreement as they would apply to CRO, before disclosing Materials and Proprietary
Information of Sponsor to such sub-contractor. 

        14.3 CRO
shall not relocate the Services to a different geographical location without the prior written consent of the Sponsor, such consent not to be unreasonably withheld. 

15.   Notices  

        Any notice (the "Notice") required to be given for the purposes of this Agreement shall be given by sending the same by registered mail, facsimile or
e-mail to, or by delivering the same by hand at, the relevant address shown in this Agreement or such other address as shall have been notified (in accordance with this clause) by the
party hereto concerned as being its address for the purposes of this clause. Any Notice so sent upon receipt, as shown by written evidence or confirmation, provided that any Notice sent by facsimile
shall be deemed to have been served on the next business day following the date of despatch thereof. 

16.   Independent Contractors  

        16.1 The
relationship of the parties hereto is that of Independent Contractors and neither party shall hold itself out to third parties, as purporting to act on behalf of,
or serving as an agent of, the other party. 

        16.2 Save
as detailed in clause 10 above neither party shall incur liability on behalf of the other, or in any way pledge or purport to pledge the credit of the other
or make contracts on behalf of the other. 

17.   Severability  

        17.1 Each
of the restrictions and provisions contained in this Agreement and in each clause and sub-clause hereof shall be construed as independent of every
other restriction and provision to the effect that if any provision of this Agreement or the application of any provision to any person, firm or company or in any circumstances shall be determined to
be invalid or unenforceable, then save as provided in clause 16.2 below, such determination shall not affect any other provision of the Agreement 

or
the application of any such provision to any person, firm or company or circumstances all of which other provisions shall remain in full force and effect. 

        17.2 In
the event that any provision of this Agreement shall be deemed to be invalid or unenforceable by a court of law of competent jurisdiction or other competent
authority in any way that shall substantially alter the relationship between the parties hereto or the advantages derived from such relationship then the parties shall on request from either of them
enter into bona fide negotiations directed towards agreeing a modification to this Agreement to restore the situation if practicable or to compensate for such alteration if not. If the parties are
unable to agree on such modification or compensation within 12 weeks after the notice request has been received by the party not affected then either party may terminate this agreement. 

18.   Precedence  

        In the event of any inconsistency between any provision of this Agreement and the Order or the Protocol, the provision of this Agreement shall govern and prevail,
provided, however, that if such provision shall be inconsistent with any protocol of a study in existence prior to the date this Agreement is effective, the parties will attempt in good faith to reach
a mutually satisfactory resolution of such inconsistency. 

19.   Waiver  

        The failure of either party at any time to require performance by the other of any of the provisions of this Agreement shall in no way affect the full right to
require such performance at any time thereafter. Nor shall the waiver, indulgence or toleration by either party of a breach of any of the provisions hereof by another be taken or held to be a waiver,
indulgence or toleration of any succeeding breach of such provision or as a waiver, indulgence or toleration of the breach thereof. 

20.   Entire Agreement  

        20.1 This
Agreement together with all Orders and the Protocol embodies the entire understanding of the parties in relation to the subject matter hereof and there are no
promises, terms, conditions and obligations, oral or written, express or implied, other than those contained herein. 

        20.2 No
amendment or variation in this Agreement shall be valid and effective unless in writing and signed on behalf of both parties. Following any such amendment references
to "this Agreement" shall be deemed to mean this Agreement so amended. 

21.   Force Majeure  

        No party shall be liable for any delay in performance or failure to perform this Agreement if due to an act or occurrence beyond the reasonable control of the
respective party, but the affected party shall promptly upon the occurrence of such an event so inform the other party in writing stating that such event has delayed or prevented its performance
hereunder and thereafter such party shall take all action within its power to comply with the terms of this Agreement as fully and promptly as possible. 

22.   Governing Law  

        This Agreement shall be governed by and construed in accordance with Austrian law without giving effect to any conflict of law principles or the United Nations
Convention on International Sale of Goods or any other law. All claims arising in connection with or arising out of this Agreement shall be resolved by the competent court in Vienna/City (Wien Innere
Stadt). 

Signed
by: 

	/s/ [ILLEGIBLE]
	 	17.12.02	 	 	 	 
	

FOR AND ON BEHALF OF CRO	
 	

 	
 	

 	
 	

 
	

/s/ [ILLEGIBLE]
	
 	

17.12.2002	
 	

/s/ [ILLEGIBLE]
	
 	

17.12.02
	

FOR AND ON BEHALF OF

Sponsor	
 	

 	
 	

 	
 	

[igeneon LOGO]
 Immunotherapy of Cancer
	

 	
 	

 	
 	

 	
 	

IGENEON Krebs-Immuntherapie

Forschungs- und Entwicklungs-AG

Brunner Strasse 59

A-1230 Wien

Tel. +43-1-869 8050-235

QuickLinks

Exhibit 10.34QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.35    
    

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

EXCLUSIVE LICENSE AGREEMENT
  BETWEEN UNIVERSITY OF TEXAS SYSTEM
  AND
  IMMUNICON CORPORATION    
    

        THIS AGREEMENT is between the BOARD OF REGENTS (BOARD) of THE UNIVERSITY OF TEXAS SYSTEM (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th
Street, Austin, Texas 78701, and IMMUNICON CORPORATION (IMMUNICON), a Pennsylvania corporation having a principal place of business located at 1310 Masons Mill II, Huntingdon Valley, Pennsylvania
19006. 

RECITALS  

        A.    IMMUNICON
independently developed certain rights in biospecific ferrofluid technology, magnetic separation technology, cell labeling technology, cell analysis platforms
and certain other reagents for the separation, isolation, enrichment and detection of rare cells; 

        B.    UT
SOUTHWESTERN independently developed certain rights in antibodies and other biomaterials useful in identifying and characterizing specific cell types of epithelial
origin; 

        C.    BOARD
and IMMUNICON entered into a COLLABORATIVE RESEARCH AGREEMENT dated July 8, 1997, directed to development of products relating to immunodetection of
circulating tumor cells and utilizing pre-existing rights of BOARD and IMMUNICON; 

        D.    BOARD
and IMMUNICON jointly own certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED SUBJECT MATTER, which were developed at The University of Texas
Southwestern Medical Center at Dallas (UT SOUTHWESTERN), located at 5323 Harry Hines Boulevard, Dallas, Texas 75235, a component institution of SYSTEM under the COLLABORATIVE RESEARCH AGREEMENT; 

        E.    BOARD
desires to have the LICENSED SUBJECT MATTER developed and used for the benefit of IMMUNICON, UT INVENTORS, BOARD, and the public as outlined in BOARD'S Intellectual
Property Policy; 

        F.     IMMUNICON
wishes to obtain a license from BOARD to practice LICENSED SUBJECT MATTER; and 

        G.    IMMUNICON
intends to sponsor research relating to LICENSED SUBJECT MATTER at UT SOUTHWESTERN to further develop LICENSED SUBJECT MATTER and identify related technologies
and has agreed to execute an appropriate sponsored research agreement (SPONSORED RESEARCH AGREEMENT) in the form attached hereto as Exhibit "A" concurrently with the execution of this AGREEMENT. 

        NOW,
THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties agree as follows: 

I. EFFECTIVE DATE  

        This AGREEMENT is effective June 1, 1999 (EFFECTIVE DATE). 

1

 
II. DEFINITIONS  

        As used in this AGREEMENT, the following terms have the meanings indicated: 

        2.1   AFFILIATE
means any business entity more than 50% owned by IMMUNICON, any business entity which owns more than 50% of IMMUNICON, any business entity that is more than
50% owned by a business entity that owns more than 50% of IMMUNICON, or any business entity where IMMUNICON has effective management control, as defined by Generally Accepted Accounting Principles. 

        2.2   UT
INVENTORS (or singly, UT INVENTOR) means Jonathan Uhr, M.D., Professor, UT SOUTHWESTERN, and Emilian Racila, Ph.D., Assistant Instructor, UT SOUTHWESTERN. 

        2.3   LICENSED
FIELD means isolation, enrichment and characterization of circulating epithelial cells, and determination of their relationship to cancer disease states. 

        2.4   LICENSED
PRODUCT means any product SOLD by IMMUNICON comprising LICENSED SUBJECT MATTER pursuant to this AGREEMENT. 

        2.5   LICENSED
SUBJECT MATTER means inventions and discoveries covered by PATENT RIGHTS or TECHNOLOGY RIGHTS within LICENSED FIELD. 

        2.6   LICENSED
TERRITORY means the world. 

        2.7   NET
SALES means the gross revenues received by IMMUNICON from the SALE of LICENSED PRODUCTS less sales and/or use taxes actually paid, import and/or export duties
actually paid, outbound transportation prepaid or allowed, amounts allowed or credited due to returns (not to exceed the original billing or invoice amount), and amortization of instrumentation cost
included in the cost of reagents and other consumable products under reagent rental contracts, the latter in no circumstance to exceed [**]% of the total cost of any such
reagent rental contract. 

        2.8   PATENT
RIGHTS means BOARD'S rights in information or discoveries (i) covered by patents and/or patent applications set forth in Exhibit "B", and any and all
divisions, continuations, continuations-in-part, reissues, reexaminations or extensions thereof, and any and all foreign counterparts of any such patent applications, and any
and all patents which may issue from any such patent applications worldwide, and (ii) arising from activities sponsored by IMMUNICON under the SPONSORED RESEARCH AGREEMENT attached hereto as
Exhibit "A". 

        2.9   SELL,
SALE or SOLD means the transfer or disposition of a LICENSED PRODUCT for value to a party other than IMMUNICON or an AFFILIATE. 

        2.10 TECHNOLOGY
RIGHTS means BOARD'S rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols,
techniques, software, designs, drawings or data created by UT INVENTORS at UT SOUTHWESTERN before the EFFECTIVE DATE relating to LICENSED PRODUCTS or IDENTIFIED PRODUCTS which are not covered by
PATENT RIGHTS but which are necessary for practicing the invention covered by PATENT RIGHTS (i) prior to the valid term of the SPONSORED RESEARCH AGREEMENT and not obligated to any third party,
or (ii) during the valid term of the SPONSORED RESEARCH AGREEMENT. 

III. WARRANTY: SUPERIOR-RIGHTS  

        3.1   Except
for the rights, if any, of the Government of the United States, as set forth below, BOARD represents and warrants its belief that (i) it is the owner of
its right, title, and interest in and to LICENSED SUBJECT MATTER, (ii) it has the right to grant licenses thereunder, and (iii) it has not knowingly granted licenses thereunder to any
other entity that would restrict rights granted to IMMUNICON except as stated herein. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

2

 

        3.2   IMMUNICON
understands that the LICENSED SUBJECT MATTER may have been developed under a funding agreement with the Government of the United States of America and, if so,
that the Government may have certain rights relative thereto. This AGREEMENT is explicitly made subject to the Government's rights under any agreement and any applicable law or regulation. If there is
a conflict between an agreement, applicable law or regulation and this AGREEMENT, the terms of the Government agreement, applicable law or regulation shall prevail. 

        3.3   IMMUNICON
understands and acknowledges that BOARD, by this AGREEMENT, makes no representation as to the operability or fitness for any use, safety, efficacy, ability to
obtain regulatory approval, patentability, and/or breadth of the LICENSED SUBJECT MATTER. BOARD, by this AGREEMENT, also makes no representation as to whether there are any patents now held, or which
will be held, by others or by BOARD in the LICENSED FIELD, nor does BOARD make any representation that the inventions contained in PATENT RIGHTS do not infringe any other patents now held or that will
be held by others or by BOARD. 

        3.4   IMMUNICON,
by execution hereof, acknowledges, covenants and agrees that it has not been induced in anyway by BOARD, SYSTEM, UT SOUTHWESTERN or its employees to enter
into this AGREEMENT, and further warrants and represents that (i) it has conducted sufficient due diligence with respect to all items and issues pertaining to this Article III and all
other matters pertaining to this AGREEMENT; and (ii) IMMUNICON has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due
diligence, and agrees to accept all risks inherent herein. 

IV. LICENSE  

        4.1   BOARD
hereby grants to IMMUNICON a royalty-bearing, exclusive license under LICENSED SUBJECT MATTER to use, have used, manufacture, have manufactured, SELL and/or have
SOLD LICENSED PRODUCTS within the LICENSED TERRITORY and LICENSED FIELD. This grant is subject to the payment by IMMUNICON to BOARD of all consideration as provided herein, and is further subject to
rights retained by BOARD to: 

	(a)
	Publish
the general scientific findings from research related to LICENSED SUBJECT MATTER subject to the terms of Article XIII, Confidential Information; and Section 8 of
the SPONSORED RESEARCH AGREEMENT of EXHIBIT "A."

	(b)
	Use
LICENSED SUBJECT MATTER for research, teaching and other educationally-related purposes. 

        4.2   IMMUNICON
may extend the license granted herein to any AFFILIATE if the AFFILIATE consents to be bound by this AGREEMENT to the same extent as IMMUNICON. 

        4.3   IMMUNICON
may grant sublicenses consistent with this AGREEMENT if the sublicensee consents to be bound by this AGREEMENT to the same extent as IMMUNICON, including the
payment of royalties whether or not paid to IMMUNICON by a sublicensee. IMMUNICON must deliver to BOARD a true and correct copy of each sublicense granted by IMMUNICON, and any modification or
termination thereof, within 30 days after execution, modification, or termination. Any sublicenses granted by IMMUNICON for use of LICENSED SUBJECT MATTER shall provide for the termination of
the sublicense, or the conversion of the sublicense to a license directly between such sublicensees and UT BOARD, upon termination of this AGREEMENT under Article VII. Such conversion is
contingent upon acceptance by the sublicensee of the remaining provisions of this AGREEMENT, and is subject to approval by UT BOARD, such approval not to be unreasonably withheld. 

3

 

V. PAYMENTS AND REPORTS  

        5.1   In
consideration of rights granted by BOARD to IMMUNICON under this AGREEMENT, IMMUNICON will pay BOARD the following: 

	(a)
	A
non-refundable annual license maintenance royalty in the amount of $25,000 is due within 30 days of the later of the third anniversary of the EFFECTIVE DATE of
this AGREEMENT, or the termination date of the SPONSORED RESEARCH AGREEMENT, if, by mutual consent, the term of the SPONSORED RESEARCH AGREEMENT is extended beyond the three year term set forth in
Section 2.2 of Exhibit "A"; and

	(b)
	A
running royalty equal to [**]% of NET SALES for LICENSED PRODUCTS; and

	(c)
	Reimbursement
of previously incurred patent expenses, not to exceed $15,000, due within thirty days of the EFFECTIVE DATE. 

        5.2   In
the event that IMMUNICON pays a royalty to a third party for use of patented rights or technology rights necessary to materially enable the function of any LICENSED
PRODUCT, IMMUNICON shall be entitled to a credit against royalties otherwise due BOARD hereunder for the actual amount of all such royalties paid to such third party or parties; provided, however,
that that the portion of such credit taken in any royalty period hereunder shall not exceed a total amount in such period that would result in BOARD receiving a payment for such period equaling a
royalty of less than [**]% of NET SALES for such period. 

        5.3   During
the Term of this AGREEMENT and for 1 year thereafter, IMMUNICON agrees to keep complete and accurate records of its and its sublicensees' SALES and NET
SALES of LICENSED PRODUCTS under the license granted in this AGREEMENT in sufficient detail to enable the royalties payable hereunder to be determined. IMMUNICON agrees to permit BOARD or its
representatives, at BOARD'S expense, to periodically examine its books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report required
under this AGREEMENT, provided that no more than one examination may be conducted during any calendar year, and any such examination will occur only after at least ten business days prior written
notice. If the amounts due to BOARD are determined to have been underpaid by more than 5%, IMMUNICON will pay the cost of the examination and accrued interest at the prime rate in effect at The Chase
Manhattan Corporation plus one percent, unless such interest rate is greater than the highest allowable rate by law, in which case the interest rate shall be the highest allowable rate by law. If the
amounts due to BOARD are determined to have overpaid, such overpayment will be credited against future royalty payments due to BOARD. 

        5.4   Within
45 days after March 31, June 30, September 30, and December 31, beginning immediately after the EFFECTIVE DATE, IMMUNICON must
deliver to BOARD a true and accurate written report, even if no payments are due BOARD, giving the particulars of the business conducted by IMMUNICON and its sublicensee(s), if any exist, during the
preceding 3 calendar months under this AGREEMENT as are pertinent to calculating payments hereunder. This report will include at least: 

the
quantities of LICENSED SUBJECT MATTER that it has produced; 

the
total SALES; 

the
calculation of royalties thereon; and 

the
total royalties computed and due BOARD. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

4

 

        Simultaneously
with the delivery of each report, IMMUNICON must pay to BOARD the amount, if any, due for the period of each report. 

        5.5   Within
45 days after each anniversary of the EFFECTIVE DATE, irrespective of having a first SALE or offer for SALE, IMMUNICON must deliver to BOARD a written
progress report as to IMMUNICON'S (and any sublicensee's) efforts and accomplishments during the preceding year in diligently commercializing LICENSED SUBJECT MATTER in the LICENSED TERRITORY and
IMMUNICON'S (and sublicensee's) commercialization plans for the upcoming year. 

        5.6   All
amounts payable here by IMMUNICON must be paid in United States funds without deductions for taxes, assessments, fees, or charges of any kind. Checks must be payable
to UT SOUTHWESTERN and mailed to: 

Ray
Wheatley

Director for Technology Development

Office for Technology Development

UT Southwestern Medical Center

5323 Harry Hines Boulevard

Dallas, Texas 75235-9094 

VI. COMMON STOCK: EQUITY OWNERSHIP  

        In consideration of the rights granted to IMMUNICON by BOARD in this AGREEMENT, IMMUNICON will, upon execution of this AGREEMENT, issue
BOARD[**]. 

VII. TERM AND TERMINATION  

        7.1   The
term of this AGREEMENT is from the EFFECTIVE DATE to the full end of the term or terms for which PATENT RIGHTS have not expired or, if only TECHNOLOGY RIGHTS are
licensed and no PATENT RIGHTS are applicable, for a term of 15 years. With mutual consent, however, the term of this AGREEMENT may be extended under the terms otherwise set forth herein. 

        7.2   Any
time after 2 years from the EFFECTIVE DATE, BOARD and UT SOUTHWESTERN have the right to terminate the exclusivity of this license in any national political
jurisdiction in the LICENSED TERRITORY if IMMUNICON, within 90 days after receiving written notice from UT SOUTHWESTERN of intended termination of exclusivity, fails to provide written evidence
satisfactory to UT SOUTHWESTERN that IMMUNICON or its sublicensees has commercialized or is actively attempting to commercialize a licensed invention in such jurisdiction(s). 

        7.3   Any
time after 3 years from the Effective Date, BOARD and UT SOUTHWESTERN have the right to terminate this license in any national political jurisdiction in the
LICENSED TERRITORY if IMMUNICON, within 90 days after receiving written notice from UT SOUTHWESTERN of intended termination, fails to provide written evidence satisfactory to UT SOUTHWESTERN
that IMMUNICON or its sublicensees has commercialized or is actively attempting to commercialize a licensed invention in such jurisdiction(s). 

        7.4   The
following definitions apply to Article 7: (i) "Commercialize" means having SALES of LICENSED PRODUCTS in such jurisdiction. (ii) "Active
attempts to commercialize" means having SALES of LICENSED PRODUCTS or an effective, ongoing and active research, development, manufacturing, marketing, sales, or business development and/or sublicense
program as appropriate, directed toward obtaining regulatory approval, production or SALES of LICENSED PRODUCTS in any jurisdiction, and plans acceptable to UT SOUTHWESTERN to commercialize licensed
inventions in the jurisdiction(s) that UT SOUTHWESTERN intends to terminate. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

5

 

        7.5   This
AGREEMENT will earlier terminate: 

	(a)
	automatically
if IMMUNICON becomes bankrupt or insolvent and/or if the business of IMMUNICON is placed in the hands of a receiver, assignee, or trustee, whether by voluntary act of
IMMUNICON or otherwise; or

	(b)
	upon
90 days written notice from BOARD if IMMUNICON breaches or defaults on its obligation to make payments (if any are due) or reports, in accordance with the terms of
Article V hereunder, unless, before the end of the 90 day period, IMMUNICON has cured the default or breach and so notifies BOARD, stating the manner of the cure; or

	(c)
	upon
90 days written notice if IMMUNICON breaches or defaults on any other obligation under this AGREEMENT, unless, before the end of the 90 day period, IMMUNICON has
cured the default or breach and so notifies BOARD, stating the manner of the cure; or

	(d)
	at
any time by mutual written agreement between IMMUNICON, UT SOUTHWESTERN and BOARD, upon 60 days written notice to all parties and subject to any terms herein which survive
termination; or

	(e)
	under
the provisions of Paragraphs 7.2 and 7.3 if invoked; or

	(f)
	if
the SPONSORED RESEARCH AGREEMENT is terminated prior to its full three year term. 

        7.6   If
this AGREEMENT is terminated for any cause: 

	(a)
	nothing
herein will be construed to release either party of any obligation matured prior to the effective date of the termination;

	(b)
	after
the effective date of the termination, IMMUNICON may SELL all LICENSED PRODUCTS and parts therefor it has on hand at the date of termination, if it pays earned royalties thereon
according to the terms of Article V;

	(c)
	IMMUNICON
will be bound by the provisions of Articles XI, XII, and XIII of this AGREEMENT; and

	(d)
	any
rights or obligations of the parties hereunder that have accrued prior to termination shall survive termination. 

VIII. INFRINGEMENT BY THIRD PARTIES  

        8.1   IMMUNICON
and BOARD shall provide the other party with prompt written notification of alleged infringement by any third party of the PATENT RIGHTS. 

        8.2   IMMUNICON,
at its expense, must enforce any patent exclusively licensed hereunder against infringement by third parties and it is entitled to retain recovery from such
enforcement. IMMUNICON must pay BOARD a royalty on any monetary recovery if the monetary recovery is for damages or a reasonable royalty in lieu thereof. If IMMUNICON does not file suit against a
substantial infringer of a patent within 6 months of knowledge thereof, then BOARD may enforce any patent licensed hereunder on behalf of itself and IMMUNICON, BOARD retaining all recoveries
from such enforcement and/or reducing the license granted hereunder to non-exclusive. 

        8.3   In
any infringement suit or dispute, the parties agree to cooperate fully with each other. At the request and expense of the party bringing suit, the other party will
permit access to all relevant personnel, records, papers, information, samples, specimens, etc., during regular business hours. 

6

 

IX. ASSIGNMENT  

        This AGREEMENT may not be assigned by IMMUNICON without the prior written consent of BOARD, which will not be unreasonably withheld. However, this AGREEMENT shall
survive sale, merger or acquisition of IMMUNICON and shall be subject to written approval by BOARD. 

X. PATENT MARKING  

        IMMUNICON must permanently and legibly mark all products and documentation manufactured or sold by it under this AGREEMENT with a patent notice as may be
permitted or required under Title 35, United States Code. 

XI. INDEMNIFICATION  

        IMMUNICON agrees to indemnify and hold harmless BOARD, SYSTEM, UT SOUTHWESTERN, its Regents, officers, agents and employees from and against any claims, demands,
liability, loss, damage or causes of action whatsoever, including without limitation those arising on account of any injury or death of persons or damage of property caused by, or arising out of, or
resulting from, the exercise or practice of the license granted hereunder by IMMUNICON, its AFFILIATES or their officers employees agents or representatives; provided, however, that the following is
excluded from IMMUNICON'S obligation to indemnify and hold harmless: 

	(a)
	the
negligent failure of UT SOUTHWESTERN to substantially comply with any applicable FDA or other governmental requirements; or

	(b)
	the
negligence or willful malfeasance of any Regent, officer, agent or employee of BOARD, SYSTEM, or UT SOUTHWESTERN. 

 XII. USE OF NAME  

        IMMUNICON may not use the name of UT INVENTORS, UT SOUTHWESTERN, SYSTEM or BOARD without express written consent of BOARD, except as required by law. BOARD may
not use the name of IMMUNICON or its inventors without express written consent of IMMUNICON, except as required by law. 

XIII. CONFIDENTIAL INFORMATION AND PUBLICATION  

        13.1 BOARD
and IMMUNICON each agree that all information contained in documents marked "confidential" and forwarded to one by the other (i) are to be received in
strict confidence, (ii) used only for the purposes of this AGREEMENT, and (iii) not disclosed by the recipient party, its agents or employees without the prior written consent of the
other party, except to the extent that the recipient party can establish competent written proof that such information: 

	(a)
	was
in the public domain at the time of disclosure;

	(b)
	later
became part of the public domain through no act or omission of the recipient party, it's employees, agents, successors or assigns;

	(c)
	was
lawfully disclosed to the recipient party by a third party having the right to disclose it;

	(d)
	was
already known by the recipient party at the time of disclosure;

	(e)
	was
independently developed by the recipient; or

	(f)
	is
required by law or regulation to be disclosed. 

        13.2 Each
party's obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other party's confidential information as it uses
to protect its own confidential 

7

 

information.
This obligation shall exist while this AGREEMENT is in force and for a period of 3 years thereafter. 

        13.2 UT
SOUTHWESTERN will submit its manuscript for any proposed publication of research carried out under the SPONSORED RESEARCH AGREEMENT in accordance with
Section 7 of the SPONSORED RESEARCH AGREEMENT. 

XIV. PATENTS AND INVENTIONS  

        As stated in 5.1(c) above, IMMUNICON shall reimburse UT SOUTHWESTERN and for all previously incurred patent expenses not to exceed $15,000. In addition,
IMMUNICON, at IMMUNICON'S election, shall either (i) reimburse UT SOUTHWESTERN for all reasonable out-of-pocket expenses for filing, prosecuting, enforcing and
maintaining PATENT RIGHTS licensed exclusively under this AGREEMENT within 30 days after receipt of written notice from BOARD, or (ii) pay directly to law firm all future expenses for
filing, prosecuting, enforcing and maintaining PATENT RIGHTS licensed exclusively under this AGREEMENT. Upon IMMUNICON'S request, UT SOUTHWESTERN will prepare and file appropriate patent applications
covering LICENSED SUBJECT MATTER, and IMMUNICON shall bear the actual cost incurred in connection with searching, preparing, filing, prosecuting and maintaining same. If IMMUNICON notifies UT
SOUTHWESTERN that it does not intend to pay costs associated with any patent application which UT SOUTHWESTERN believes should be prepared and filed, then UT SOUTHWESTERN may file such application at
its own expense and IMMUNICON shall have no rights under this AGREEMENT to said patent application or any patent which may issue therefrom. UT SOUTHWESTERN shall provide IMMUNICON with a copy of any
and all patent applications filed for which IMMUNICON is bearing the actual cost of filing, as well as copies of any documents received or filed during prosecution thereof. Similarly, if IMMUNICON
elects to pay directly patent expenses in accordance with IMMUNICON'S right as set forth above, IMMUNICON shall instruct outside counsel (approved by BOARD, such approval not to be unreasonably
withheld) to provide UT SOUTHWESTERN with copies of all patent-related communications, including, but not limited to, invoices and provide evidence of direct payment of such expenses incurred to UT
SOUTHWESTERN within 30 days of receipt of such invoices. The parties each shall have the right to review and comment
upon the wording of the specifications, claims and responses to Office Actions prior to their submission to the U.S. Patent and Trademark Office for any and all applications for which IMMUNICON is
either reimbursing or paying directly patent expenses. 

XV. ALTERNATE DISPUTE RESOLUTION  

        Any dispute or controversy arising out of or relating to this AGREEMENT, its construction or its actual or alleged breach will be decided by mediation. If the
mediation does not result in a resolution of such dispute or controversy, it will be finally decided by an appropriate method of alternate dispute resolution, including without limitation,
arbitration, in accordance with the Licensing Agreement Arbitration Rules of the American Arbitration Association. The arbitration panel will include members knowledgeable in the evaluation of the use
of antibodies in the detection of malignant cells. Judgment upon the award rendered may be entered in the highest court or forum having jurisdiction, state or federal. The provisions of this
Article XV will not apply to decisions on the validity of patent claims or to any dispute or controversy as to which any treaty or law prohibits such arbitration. The decision of the
arbitration must be sanctioned by a court of law having jurisdiction to be binding upon and enforceable by the parties. 

XVI. GENERAL  

        16.1 This
AGREEMENT and the SPONSORED RESEARCH AGREEMENT constitute the entire and only agreements between the parties for LICENSED SUBJECT MATTER and all other 

8

 

prior
negotiations, representations, agreements, and understandings, including the COLLABORATIVE RESEARCH AGREEMENT dated July 8, 1997, are superseded hereby. No agreements altering or
supplementing the terms hereof may be made except by a written document signed by both parties. 

        16.2 Any
notice required by this AGREEMENT must be given by facsimile transmission confirmed by personal delivery (including delivery by reputable messenger service, such as
Federal Express), or by prepaid, first class, certified mail, return receipt requested, addressed in the case of BOARD to: 

BOARD
of Regents

The University of Texas System

201 West 7th Street

Austin, Texas 78701

ATTENTION: Office of General Counsel

PHONE: (512) 499-4462

FAX: (512) 499-4523 

with
copies to: 

UT
SOUTHWESTERN

Peter H. Fitzgerald, Ph.D.

Executive Vice President for Business Affairs

5323 Harry Hines Boulevard

Dallas, Texas 75235-9013

PHONE: (214) 648-3572

FAX: (214) 648-3944 

and
to: 

Ray
Wheatley

Director for Technology Development

5323 Harry Hines Boulevard

Dallas, Texas 75235-9094

PHONE: (214) 648-1880

FAX: (214) 648-648-1889 

or
in the case of IMMUNICON to: 

Edward
L. Erickson

Chairman and Chief Executive Officer

Immunicon Corporation

1310 Mason Mill II

Huntingdon Valley, PA 19006

PHONE: (215) 938-0100

FAX: (215) 938-0437 

or
other addresses as may be given from time to time under the terms of this notice provision. 

        16.3 IMMUNICON
and BOARD must comply with all applicable federal, state and local laws and regulations in connection with its activities pursuant to this AGREEMENT. 

        16.4 This
AGREEMENT will be construed and enforced in accordance with the laws of the United States of America. 

        16.5 Failure
of BOARD to enforce a right under this AGREEMENT will not act as a waiver of that right or the ability to later assert that right relative to the particular
situation involved. 

9

 

        16.6 Headings
are included herein for convenience only and shall not be used to construe this AGREEMENT. 

        16.7 If
any part of this AGREEMENT is for any reason found to be unenforceable, all other parts nevertheless remain enforceable. 

        IN
WITNESS WHEREOF, parties hereto have caused their duly authorized representatives to execute this AGREEMENT. 

	BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	 	IMMUNICON CORPORATION
	

By	

/s/ Peter H. Fitzgerald
 Peter H. Fitzgerald, Ph.D. Executive Vice President for Business Affairs UT Southwestern	
 	

By	

/s/ Edward L. Erickson
 Edward L. Erickson

Chairman and CEO
	

Date:	

June 18, 1999
	
 	

Date:	

6/16/99

	

APPROVED AS TO FORM:	
 	

 	

 
	UT SYSTEM	 	 	 
	

By	

/s/ BethLynn Maxwell
 BethLynn Maxwell

Office of General Counsel	
 	

 	

 
	

Date:	

21 June 99
	
 	

 	

 
	

APPROVED AS TO CONTENT:	
 	

 	

 
	By	/s/ Dennis K. Stone
 Dennis K. Stone, M.D.

Vice President for Technology Development

UT Southwestern	 	 	 
	

Date:	

June 15, 1999
	
 	

 	

 

10

  

 
 

Exhibit A    
    

 
 

Sponsored Research Agreement    
    

        This Sponsored Research Agreement (the "Agreement") is made between The University of Texas Southwestern Medical Center at Dallas ("University"), a component
institution of The University of Texas System ("System") and Immunicon Corporation, a Pennsylvania corporation with its principal place of business at 1310 Mason Mill II, Huntingdon Valley, PA 19006
("Sponsor"). 

RECITALS  

        A.    Sponsor
desires that University perform certain research hereinafter described and is willing to advance funds to sponsor such research; and 

        B.    Sponsor
desires to obtain certain rights to intellectual property developed during the course of such research with a view to commercialization of such intellectual
property for the Sponsor's benefit; and 

        C.    University
is willing to perform such research and to grant certain rights to such intellectual property. 

1. EFFECTIVE DATE  

        This Agreement shall be effective as of June 1, 1999 (the "Effective Date"). 

2. RESEARCH PROGRAM  

        2.1   University
will use reasonable efforts to conduct the research program described in Attachment A ("Research Program"), and will furnish the facilities necessary to carry
out the Research Program. The Research Program will be under the direction of Jonathan Uhr, M.D. or his successor as mutually agreed to by the parties (the "Principal Investigator") and will be
conducted by the Principal Investigator at the University. 

        2.2   The
Research Program shall be performed during the period from the Effective Date through and including May 31, 2002 ("Term"). Sponsor shall have the option to
negotiate an extension of the Term under mutually agreeable support terms. Such option shall be exercised within ninety (90) days prior to the end of the Term. 

        2.3   Sponsor
understands that University's mission is advancement of knowledge, education, and patient care and, consequently, the Research Program will be designed to be
compatible with that mission. The manner of performance of the Research Program shall be determined solely by the Principal Investigator. University does not guarantee specific results. 

        2.4   Sponsor
understands that University and/or System may be involved in similar research through other researchers on behalf of itself and others. University shall be free
to continue such research provided that it is conducted separately and by different investigators from the Research Program, and Sponsor shall not gain any rights via this Agreement to such other
research. 

        2.5   University
does not guarantee that any intellectual property rights will result from the Research Program, that the scope of any intellectual property rights obtained
will cover Sponsor's commercial interest, or that any such intellectual property rights will be free of dominance by others independent of the Research Program. 

1

 

3. COMPENSATION  

        3.1   As
consideration for the performance by University of its obligations under this Agreement, Sponsor will pay the University an amount equal to its projected expenditures
and reasonable overhead in conducting the Research Program, which is estimated to be $190,000 per year for three years, for a total of $570,000. An initial payment of $47,250 shall be made at the time
of execution of this Agreement, and subsequent equal quarterly advance payments of $47,250 each shall be made thereafter through the Term of this Agreement. 

        3.2   University
shall maintain all Research Program funds in a separate account and shall expend such funds for wages, supplies, equipment, travel, and other operating
expenses in connection with the Research Program. It is understood that any funds in this separate account at the conclusion of the Research Program shall be retained by University. 

        3.3   University
shall retain title to all equipment purchased and/or fabricated by it with funds provided by Sponsor under this Agreement. 

4. PROVISION OF RESEARCH MATERIALS  

        4.1   Sponsor
shall provide University with certain materials and equipment free of charge as needed by Principal Investigator to fulfill the aims of the Research Program.
Specifically, Sponsor will supply sufficient quantities of reagents (e.g.,[**]) to process the blood samples of subjects and controls as specified in Attachment A, which
attachment is subject to amendment from time-to-time by mutual agreement. Sponsor shall also supply the necessary equipment and software to perform the basic epithelial cell
assays required by Attachment A. However, title to such equipment and software will remain with Sponsor, and Sponsor shall be solely responsible for such equipment and software. Additionally, Sponsor
shall make a diligent, but commercially reasonable effort, to obtain from third party sources those materials that are important to explore markers (e.g., mammaglobin) that can be used to determine
the organ-of-origin of epithelial cells from subjects' peripheral blood. 

        4.2   University
shall use the materials provided by Sponsor only for the purposes contemplated under the terms of this Agreement. 

        4.3   Materials
shall be used only at University under the direction of the Principal Investigator or others working under his direct supervision. 

        4.4   Materials
shall not be transferred to any other party at University or outside University without the prior written consent of the Sponsor. 

5. CONSULTATION AND REPORTS  

        5.1   Sponsor's
designated representative for consultation and communications with the Principal Investigator shall be Leon W.M.M. Terstappen, M.D., Ph.D., Senior Vice
President of Research and Development, or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator ("Designated Representative"). 

        5.2   During
the Term of the Agreement, Sponsor's representatives may consult informally with University's representatives regarding the project, both personally and by
telephone. Access to work carried on in University laboratories in the course of these investigations shall be entirely under the control of University personnel but shall be made available on a
reasonable basis. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

2

 

        5.3   The
Principal Investigator will make oral reports at reasonable intervals as requested by Sponsor's Designated Representative. At the conclusion of each year, the
Principal Investigator shall submit to Sponsor a written report summarizing the work. The Principal Investigator shall also submit a comprehensive final report within one hundred twenty
(120) days of termination of the Agreement which shall contain, but which need not be limited to, the following information: 

	a.
	A
summary of expenses of Research Program.

	b.
	A
report of the activities undertaken and accomplishments achieved by the University under the Research Program. 

6. PUBLICITY  

        Neither party (without the other party's consent, such consent not to be unreasonably withheld) shall make reference to the other in a press release or any other
written statement in connection with work performed under this Agreement, if it is intended for use in the public media, except as required by The Texas Public Information Act or other law, regulation
or published rule of local, state or national governments and their duly empowered regulatory agencies. University, however, shall have the right to acknowledge Sponsor's support of the investigations
under this Agreement in scientific or academic publications and other scientific or academic communications, without Sponsor's prior approval. In any such statements, the parties shall describe the
scope and nature of their participation accurately and appropriately. Press releases describing a new finding shall have the conventional embargo until publication of the scientific paper containing
such new finding. 

7. PUBLICATION AND PATENT FILING  

        7.1   University
and Principal Investigator have the right to publish or otherwise publicly disclose information gained in the course of this Agreement. In order to avoid loss
of patent rights as a result of premature public disclosure of patentable information, University will submit any prepublication materials to Sponsor
for review and comment at least sixty (60) days prior to planned submission for publication. Sponsor shall notify University within thirty (30) days of receipt of such materials whether
it desires to seek protection of any intellectual property which may be disclosed by publication of the materials. University shall have the final authority to determine the scope and content of any
publications. 

        7.2   Both
parties agree to promptly notify the other of the development of any inventions during the course of the Research Program, and to cooperate in the determination of
inventorship of such inventions. It is agreed that Sponsor shall be responsible for the filing and prosecution of patent applications on any inventions which are owned jointly by Sponsor and
University, provided that University must consent to the choice of patent counsel, such consent not to be unreasonably withheld. University shall be responsible for the filing and prosecution of any
patent applications for any inventions which are owned solely by University. The filing party shall provide copies of all applications and documentation related to the prosecution of any patents for
inventions arising from the performance of the Research Program to the other party in order to allow the other party the opportunity to review and comment thereon. 

        7.3   It
is understood that the University investigators may discuss the research being performed under this Agreement with other investigators but shall not reveal
information which is Sponsor's Confidential Information under Article 8. In the event any joint inventions result form such discussions, University shall grant to Sponsor the rights outlined in
Article 9 of this Agreement, to the extent these are not in conflict with obligations to another party as a result of the involvement of the other investigator(s). In this latter case,
University shall, in good faith, exercise reasonable efforts to enable Sponsor to obtain rights to the joint invention. 

3

 

8. CONFIDENTIAL INFORMATION  

        8.1   The
parties may wish, from time to time, in connection with work contemplated under this Agreement, to disclose confidential information to each other ("Confidential
Information"). Each party will use reasonable efforts to prevent the disclosure of any of the other party's Confidential Information to third parties for a period of three (3) years from
receipt thereof, provided that the recipient party's obligation shall not apply to information that as to which the recipient party can establish, on the basis of its written records: 

	(1)
	is
not disclosed in writing or reduced to writing and so marked with an appropriate confidentiality legend within thirty (30) days of disclosure;

	(2)
	is
already in the recipient party's possession at the time of disclosure thereof;

	(3)
	is
or later becomes part of the public domain through no fault of the recipient party;

	(4)
	is
received from a third party having no obligations of confidentiality to the disclosing party;

	(5)
	is
independently developed by the recipient party; or

	(6)
	is
required by law or regulation to be disclosed. 

        8.2   In
the event that information is required to be disclosed pursuant to subsection 8.1(6) above, the party required to make disclosure shall notify the other to allow that
party to assert whatever exclusions or exemptions may be available to it under such law or regulation. 

        8.3   It
is understood that any specific item of Confidential Information that is disclosed pursuant to this Agreement shall not be considered to be in the public domain or in
the recipient party's possession merely because it is embraced by more general information which is in the public domain or in the recipient party's possession. 

9. PATENTS, COPYRIGHTS, AND TECHNOLOGY RIGHTS  

        Title to all inventions and discoveries made by University resulting from the research performed hereunder shall reside in University. Title to all inventions and
discoveries made jointly by Sponsor and University resulting from the research performed hereunder shall reside jointly in Sponsor and University. University hereby grants to Sponsor an exclusive,
worldwide, royalty-bearing license to make, have made, use, have used, sell or have sold under its interests in any sole or joint invention or discovery made or conceived during the term of this
Agreement and directly resulting from the performance of research hereunder, under the terms and conditions of the Exclusive License Agreement between Sponsor and The University of Texas System Board
of Regents, which has an effective date of June 1, 1999 ("Exclusive License Agreement"). 

10. LIABILITY  

        10.1 Sponsor
agrees to indemnify and hold harmless System, University, their Regents, officers, agents and employees from any liability, loss or damage they may suffer as a
result of claims, demands, costs or judgments against them arising out of the activities to be carried out pursuant to the obligations of this Agreement, including but not limited to the use by
Sponsor of the results obtained from the activities performed by University under this Agreement; provided, however, that the following is excluded from Sponsor's obligation to indemnify and hold
harmless: 

	a.
	the
negligent failure of University to substantially comply with any applicable FDA or other governmental requirements; or

	b.
	the
negligence or willful malfeasance of any Regent, officer, agent or employee of University or System. 

4

 

        10.2 Both
parties agree that upon receipt of a notice of claim or action arising out of the activities to be carried out pursuant to the project described in Attachment A,
the party receiving such notice will notify the other party promptly. Except for actions arising under the circumstances outlined in Section 10.1 (a) and (b) above, Sponsor
agrees, at its own expense, to provide attorneys to defend against any actions brought or filed against University, System, their Regents, officers, agents and/or employees with respect to the subject
of the indemnity contained herein, whether such claims or actions are rightfully brought or filed; and subject to the statutory duty of The Texas Attorney General, University agrees to cooperate with
Sponsor in the defense of such claim or action. 

11. INDEPENDENT CONTRACTOR  

        For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be, independent contractors and not
agents or employees of the other party. Neither party shall have authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other
party, except as may be expressly provided for herein or authorized in writing. 

12. TERM AND TERMINATION  

        12.1 This
Agreement shall commence on the Effective Date and extend until the end of the Research Program as described hereinabove, unless sooner terminated in accordance
with the provisions of this Section. 

        12.2 This
Agreement may be terminated by the written agreement of both parties. 

        12.3 In
the event that either party shall be in default of its material obligations under this Agreement and shall fail to remedy such default within sixty (60) days
after receipt of written notice thereof, this Agreement shall terminate upon expiration of the sixty (60) day period. 

        12.4 Termination
or cancellation of this Agreement shall not affect the rights and obligations of the parties accrued prior to termination. As its sole liability upon
termination, Sponsor shall pay University for all reasonable non cancelable expenses incurred or committed to be expended as of the effective termination date, including salaries for appointees for
the remainder of their appointment; provided, however, that such appointments shall not extend beyond the original expiration date of this Agreement. 

        12.5 Any
provisions of this Agreement which by their nature extend beyond termination shall survive such termination. 

13. ATTACHMENTS  

        Attachment A is incorporated and made a part of this Agreement for all purposes. 

14. ALTERNATIVE DISPUTE RESOLUTION  

        Any dispute or controversy arising out of or relating to this Agreement, its construction or its actual or alleged breach will be decided by mediation. If the
mediation does not result in a resolution of such dispute or controversy, it will be finally decided by an appropriate method of alternate dispute resolution, including without limitation,
arbitration, conducted in accordance with the Rules of the American Arbitration Association. The arbitration panel will include members knowledgeable in the evaluation of the use of antibodies in the
detection of malignant cells. Judgment upon the award rendered may be entered in the highest court or forum having jurisdiction, state or federal. The provision of this Article 14 will not
apply to decisions on the validity of patent claims or to any dispute or controversy as to which any treaty or law prohibits such arbitration. The decision of the arbitration 

5

 

must
be sanctioned by a court of law having jurisdiction to be binding upon and enforceable by the parties. 

15. GENERAL  

        15.1 This
Agreement may not be assigned by either party without the prior written consent of the other party, which will not be unreasonably withheld. However, this
Agreement shall survive the sale, merger or acquisition of Sponsor and shall be subject to written approval by University. Furthermore, University may assign its right to receive payments hereunder. 

        15.2 This
Agreement and the Exclusive License Agreement constitute the entire and only agreements between the parties relating to the Research Program, and all prior
negotiations, representations, agreements and understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by means of a written document signed by
the duly authorized representatives of the parties. In the event of a conflict in the terms between this Agreement and the Exclusive License Agreement, the terms of the Exclusive License Agreement
shall control. 

        15.3 Any
notice required by this Agreement by Articles 8, 9, or 11 shall be given by prepaid, first class, certified mail, return receipt requested, addressed in the case of
University to: 

The
University of Texas System, O.G.C.

201 West 7th Street

Austin, TX 78701

Attention: Intellectual Property Section

FAX: (512) 499-4523

PHONE: (512) 499-4462 

The
University of Texas Southwestern

    Medical Center at Dallas

5323 Harry Hines Blvd.

Dallas, TX 75235-9062

ATTN: Gerald Mussey

              Director, Contracts Management

FAX: (214) 648-8805

PHONE: (214) 648-8748 

or
in the case of Sponsor to: 

Immunicon
Corporation

1310 Mason Mill II

Huntingdon Valley, PA 19006

ATTN: Edward L. Erickson

              Chairman and Chief Executive Officer

FAX: (215) 938-0437

PHONE: (215) 938-0100 

or
at such other addresses as may be given from time to time in accordance with the terms of this notice provision. 

6

 

        IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives. 

	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	 	IMMUNICON CORPORATOIN
	

/s/ Peter H. Fitzgerald
 Peter H. Fitzgerald

Executive Vice President for Business Affairs	
 	

/s/ Edward L. Erickson
 Edward L. Erickson

Chairman and Chief Executive Officer

	

Date	

June 18, 1999
	
 	

Date	

6/16/99

7

Attachment A to the Sponsored Research Agreement with Effective Date of June 1, 1999  

        [**] 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

EXHIBIT B    
    

	1.
	U.S.
Provisional Patent Application Serial Number 60/074,535, filed February 12, 1998, entitled "Test For Detecting, Enumerating and Characterizing Carcinoma Cells in the Blood"
(corresponding for reference purposes only to UT SOUTHWESTERN file number UTSD:568-PZ1).

	2.
	U.S.
Provisional Patent Application Serial Number 60/110,202, filed November 30, 1998, entitled "Detection and Characterization of Carcinoma Cells in the Blood" (corresponding
for reference purposes only to UT SOUTHWESTERN file number UTSD:568-PZ2).

	3.
	U.S.
Patent Application Serial Number 09/248,388, filed February 12, 1999, entitled "Methods and Reagents for the Rapid and Efficient Isolation of Circulating Cancer Cells"
(corresponding for reference purposes only to UT SOUTHWESTERN file number UTSD:568). 

QuickLinks

Exhibit 10.35

EXCLUSIVE LICENSE AGREEMENT BETWEEN UNIVERSITY OF TEXAS SYSTEM AND IMMUNICON CORPORATION

Exhibit A

Sponsored Research Agreement

EXHIBIT B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]